Diagnosis and management of Clostridium difficile infection
- PMID: 23542332
- DOI: 10.1016/j.cgh.2013.03.016
Diagnosis and management of Clostridium difficile infection
Abstract
Clostridium difficile infection (CDI) is increasing in frequency and severity in and out of the hospital, with a high probability of recurrence after treatment. The recent literature on CDI was reviewed using PubMed to include recent publications dealing with diagnosis and therapy. Real-time polymerase chain reaction is a sensitive and useful diagnostic test for CDI but there are growing concerns of false-positive test results if the rate of CDI is low in the patient population providing samples and/or if the population being studied commonly includes people with C difficile colonization. Recommended therapy of CDI includes oral metronidazole for milder cases of CDI and oral vancomycin or fidaxomicin for more severe cases, each given for 10 days. Colectomy is being performed more frequently in patients with fulminant CDI. For treatment of first recurrences the drug used in the first bout can be used again and for second recurrences longer courses of vancomycin often are given in a tapered dose or intermittently to allow gut flora reconstitution, or other treatments including fidaxomicin may be used. Bacteriotherapy with fecal transplantation is playing an increasing role in therapy of recurrent cases. Metagenomic studies of patients with CDI during successful therapy are needed to determine how best to protect the flora from assaults from antibacterial drugs and to develop optimal therapeutic approaches. Immunotherapy and immunoprophylaxis offer opportunities to prevent CDI, to speed up recovery from CDI, and to eliminate recurrent infection. Humanized monoclonal antitoxin antibodies and active immunization with vaccines against C difficile or its toxins are both in development and appear to be of potential value.
Keywords: Antibiotic-associated Diarrhea; CDI; Clostridium difficile Infection; Clostridium difficile infection; Fidaxomicin; GDH; Metronidazole; Microbiome; NAP1; North American pulse-field type 1; Oral Vancomycin; PPV; RT-PCR; glutamate dehydrogenase; positive predictive value; real-time polymerase chain reaction.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Clostridium difficile infection in older adults: a review and update on its management.Am J Geriatr Pharmacother. 2012 Feb;10(1):14-24. doi: 10.1016/j.amjopharm.2011.12.004. Epub 2012 Jan 20. Am J Geriatr Pharmacother. 2012. PMID: 22260856 Review.
-
Best strategies in recurrent or persistent Clostridium difficile infection.Surg Infect (Larchmt). 2011 Jun;12(3):235-9. doi: 10.1089/sur.2010.080. Epub 2011 Jul 18. Surg Infect (Larchmt). 2011. PMID: 21767157 Review.
-
Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?Clin Microbiol Infect. 2012 Dec;18 Suppl 6:28-35. doi: 10.1111/1469-0691.12012. Clin Microbiol Infect. 2012. PMID: 23121552 Review.
-
Challenges and opportunities in the management of Clostridium difficile infection.Expert Rev Gastroenterol Hepatol. 2014 Nov;8(8):863-74. doi: 10.1586/17474124.2014.939630. Epub 2014 Jul 11. Expert Rev Gastroenterol Hepatol. 2014. PMID: 25012255 Review.
-
Therapeutic approaches for Clostridium difficile infections.Curr Protoc Microbiol. 2013 Oct 2;30:9A.3.1-9A.3.9. doi: 10.1002/9780471729259.mc09a03s30. Curr Protoc Microbiol. 2013. PMID: 24510892
Cited by
-
Clostridioides difficile Infections: Prevention and Treatment Strategies.Adv Exp Med Biol. 2024;1449:175-186. doi: 10.1007/978-3-031-58572-2_11. Adv Exp Med Biol. 2024. PMID: 39060738 Review.
-
Clostridioides difficile Biofilm.Adv Exp Med Biol. 2024;1435:249-272. doi: 10.1007/978-3-031-42108-2_12. Adv Exp Med Biol. 2024. PMID: 38175479
-
Syndromic Panel Testing Among Patients With Infectious Diarrhea: The Challenge of Interpreting Clostridioides difficile Positivity on a Multiplex Molecular Panel.Open Forum Infect Dis. 2023 Apr 10;10(5):ofad184. doi: 10.1093/ofid/ofad184. eCollection 2023 May. Open Forum Infect Dis. 2023. PMID: 37711280 Free PMC article.
-
Fecal microbiota transplantation and its repercussions in patients with melanoma refractory to anti-PD-1 therapy: scope review.Rev Col Bras Cir. 2023 May 19;50:e20233490. doi: 10.1590/0100-6991e-20233490-en. eCollection 2023. Rev Col Bras Cir. 2023. PMID: 37222345 Free PMC article.
-
Lactulose may reduce Clostridium difficile-related diarrhea among patients receiving antibiotics.JGH Open. 2020 Jul 9;4(6):1088-1090. doi: 10.1002/jgh3.12390. eCollection 2020 Dec. JGH Open. 2020. PMID: 33319041 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
